Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
GARP vs XBI: how they differ
GARP and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
iShares MSCI USA Quality GARP ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, GARP and XBI hold 0% of their money in the same securities at the same weight.
| Holding | GARP | XBI |
|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 0.05% | 0.96% |
| INCYTE CORP | 0.05% | 1.00% |
| NATERA INC | 0.05% | 1.17% |
| NEUROCRINE BIOSCIENCES INC | 0.04% | 0.97% |
| Only in GARP | Only in XBI |
|---|---|
| KLA CORP 6.46% | Apogee Therapeutics Inc 1.49% |
| MICRON TECHNOLOGY INC 6.07% | Moderna Inc 1.41% |
| APPLE INC 4.44% | Twist Bioscience Corp 1.41% |
| NVIDIA CORP 4.16% | Oruka Therapeutics Inc 1.38% |
| MICROSOFT CORP 4.10% | Kymera Therapeutics Inc 1.36% |
| BROADCOM INC 3.96% | Viking Therapeutics Inc 1.31% |
| LAM RESEARCH CORP 3.79% | Praxis Precision Medicines Inc 1.29% |
| ELI LILLY & COMPANY 3.73% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
| GARP iShares MSCI USA Quality GARP ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | State Street |
| What it is | MSCI USA Quality GARP | SPDR S&P Biotech |
| Total return, 1 year | +29.5% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +12.0 pts | +46.5 pts |
| Expense ratio | 0.15% | 0.35% |
| Already in the S&P 500 | 94.4% | 8.5% |
| Holdings | 131 | 150 |
GARP in plain words
GARP is an index equity fund tracking the MSCI USA Quality GARP. Over the year to Sep 11, 2026 it returned +29.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.15% a year. By its holdings filed for Jun 30, 2026, 94% of the fund by weight is stocks the S&P 500 also holds, across 131 positions, with the top ten at 43.8%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, GARP or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, GARP returned +29.5% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, GARP or XBI?
- GARP charges 0.15% a year and XBI charges 0.35%, so GARP is cheaper. Fees come from each fund's prospectus.
- How much do GARP and XBI overlap with the S&P 500?
- By their latest filed holdings, 94% of GARP and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, GARP against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/GARP-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources